Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC

NCT03326947 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Neoplasm Neck

Interventions

DRUG: docetaxel, cisplatin and 5-fluorouracil

Sponsor

Shanghai Jiao Tong University School of Medicine